Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 1386 publications over 31 distinct years, with a maximum of 84 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	5	6	11
1996	6	6	12
1997	7	6	13
1998	12	12	24
1999	8	11	19
2000	7	16	23
2001	12	15	27
2002	18	17	35
2003	11	16	27
2004	24	17	41
2005	19	24	43
2006	31	25	56
2007	16	26	42
2008	19	27	46
2009	26	30	56
2010	17	27	44
2011	36	31	67
2012	32	29	61
2013	37	25	62
2014	47	28	75
2015	44	34	78
2016	41	40	81
2017	33	34	67
2018	30	28	58
2019	50	34	84
2020	39	33	72
2021	21	23	44
2022	2	29	31
2023	4	19	23
2024	18	33	51
2025	4	9	13

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Alam R, Reva A, Edwards DG, Lege BM, Munoz-Arcos LS, Reduzzi C, Singh S, Hao X, Wu YH, Tian Z, Natalee LM, Damle G, Demircioglu D, Wang Y, Wu L, Molteni E, Hasson D, Lim B, Gugala Z, Chipuk JE, Lang JE, Sparano JA, Cheng C, Cristofanilli M, Xiao H, Zhang XH, Bado IL. Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.

View in: PubMed
Lucas CG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M, Pekmezci M, Quezado M, Rodriguez FJ, Stemmer-Rachamimov A, Viskochil D, Perry A. Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1. Neuro Oncol. 2025 Mar 07; 27(3):616-624.

View in: PubMed
Strauss JD, Gilbert MR, Mehta M, Li A, Zhou R, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol. 2025 Mar 07; 27(3):767-778.

View in: PubMed
Johnson BA, Parimi V, Kamanda S, Corney DC, Choi W, Hoffman-Censits J, Kates M, McConkey DJ, Hahn NM, Matoso A. Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells. J Pathol Clin Res. 2025 Mar; 11(2):e70021.

View in: PubMed
Yarman Y, Post R, Breslin Z, Solomides CC, Gargano SM. Utility of Proliferation Markers Ki-67 and PHH3 in Predicting Malignancy in Basaloid Salivary Gland Neoplasms: A Study Using Digital Image Analysis of Cytology Cell Blocks. Diagn Cytopathol. 2025 May; 53(5):238-245.

View in: PubMed
Wei S, Patchefsky AS, Pei J, Brown SA, Basu Mallick A, Wang Z, Jiang W. PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature. Am J Clin Pathol. 2025 Feb 12; 163(2):224-230.

View in: PubMed
Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R, Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, Martinez-Outschoorn U, Cognetti DM, Curry JM, Prendergast GC, Argiris A, South AP, Linnenbach AJ, Johnson JM, Luginbuhl AJ. Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 02 03; 31(3):515-528.

View in: PubMed
Owosho AA, Gleysteen JP, Wood CB, Franklin A, Angel J, Jain R. DEK::AFF2 Squamous Cell Carcinomas of the Sinonasal Region and Temporal Bone Diagnosed After Recurrences: A Report of Two Patients. Int J Surg Pathol. 2025 Aug; 33(5):1258-1266.

View in: PubMed
Lasota J, Kaczorowski M, Chlopek M, Milek-Krupa J, Szczepaniak M, Ylaya K, Chodyna M, Izycka-Swieszewska E, Scherping A, Czapiewski P, Dziuba I, Kato Y, Halon A, Kowalik A, Miettinen M. An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy. Hum Pathol. 2025 Jan; 155:105717.

View in: PubMed
Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Feb 20; 43(6):748-758.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement